Biotechnology company developing targeted-delivery in vivo CAR-T therapies for cancer and autoimmune diseases
Biotechnology company developing targeted-delivery in vivo CAR-T therapies for cancer and autoimmune diseases. Its lead candidate GT801 uses lipid nanoparticles to generate CD19-directed CAR-T cells inside the body, aiming to avoid conventional ex vivo cell manufacturing.